Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 45 Products per page

Multiple Myeloma KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.
May 15, 2020
Find out more
Japan Regulatory Issues

$2,995.00

Historically Japan has been plagued with delays, with new drug approvals sometimes taking three or four years longer than in the US and EU.
November 2, 2016
Find out more
Stelara
Read More
Stelara (ustekinumab; Johnson & Johnson/Mitsubishi Tanabe) is a high-affinity, fully human monoclonal antibody that targets the p40 subunit of cytokines interleukin (IL)-12 and IL-23 proteins that occur in the immune system.
August 2, 2018
Find out more
Dyslipidemia KOL Insight Interview #1

$599.00

Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data
July 25, 2014
Find out more
Germany Regulatory Issues

$2,995.00

Data indicates that companies often favor Germany when choosing a reference member state (RMS) in order to gain approval under the decentralized procedure, perhaps reflecting overall a fast pace of regulatory review.
November 2, 2016
Find out more
Bladder Cancer Pricing, Reimbursement, and Access

$2,995.00

Payers are not overly worried about the cost of bladder cancer, due to the relatively small patient population in comparison to other solid tumors.
September 27, 2018
Find out more
MOR208
Read More
MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.
October 9, 2018
Find out more
U.S. Markets for Orthopedic Biomaterials for Bone Repair and Regeneration

$3,750.00

The United States (U.S.) market for orthopedic biomaterials for bone repair and regeneration, as covered by the scope of this report
May 1, 2013
Find out more
Rixubis
Read More
Developed by Baxalta (which was then acquired by Shire), Rixubis was only the second recombinant factor IX (rfIX) therapy approved for hemophilia B, and the first to be indicated for routine prophylaxis treatment in adults upon its 2013 approval.
May 4, 2018
Find out more
Idasanutlin
Read More
Idasanutlin (Roche) is an oral inhibitor of the murine double minute 2 (MDM2) protein, which blocks the interaction of MDM2 with the p53 tumor suppressor.
July 6, 2017
Find out more
Brilinta
Read More
Brilinta (ticagrelor; AstraZeneca/The Medicines Company) is an antiplatelet agent designed to inhibit blood clot formation. It works by reversibly binding to the blood platelets’ adenosine diphosphate (ADP) P2Y12 receptor…
April 14, 2016
Find out more
SaxaDapa
Read More
SaxaDapa is a fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitor Farxiga (dapagliflozin; AstraZeneca) and dipeptidyl peptidase-IV inhibitor Onglyza (dapagliflozin; AstraZeneca/Kyowa Hakko Kirin).
November 7, 2017
Find out more
Asthma and COPD KOL Interview

$599.00

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.
February 29, 2016
Find out more
Disease Analysis: Rheumatoid Arthritis
Read More
The rheumatoid arthritis (RA) market is set to experience increasing attrition due to biosimilar competition. The EU market has taken the brunt of biosimilar erosion, with earlier launches and more acceptance of biosimilars compared to other countries. Over time, biosimilar penetration is anticipated to gain more momentum as international real-world evidence builds, with long-term data supporting biosimilar efficacy and safety. This should allow physicians and patients to grow their confidence and familiarity with biosimilars, and encourage uptake.
March 24, 2022
Find out more
Acute Myeloid Leukemia (AML) KOL Interview – US, South

$599.00

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.
March 14, 2022
Find out more
Oncology: Surgical Ablation Devices Market

$4,750.00

Valued at approximately $380m in 2017, the Surgical Ablation Devices Market for Oncology is expanding at a double-digit rate, driven by the increasing global prevalence of cancer and the growing demand for better healthcare in emerging markets.
June 19, 2018
Find out more
Vibativ
Read More
Vibativ is a lipoglycopeptide antibiotic that is a semisynthetic derivative of vancomycin. The drug exhibits a dual bactericidal mechanism of action.
September 10, 2014
Find out more
Drug Pricing in the US

$2,995.00

Drug prices in the US have been the subject of intense debate over the past 2–3 years, following a surge in spending on prescription medicines and steep price increases in some categories
July 5, 2017
Find out more
Dovobet
Read More
Leo Pharma developed and launched Dovobet (also known as Daivobet, Taclonex, Xamiol, and LEO-80185), a dermatological ointment formulation of the vitamin D analog calcipotriol and the corticosteroid betamethasone dipropionate, for the treatment of…
August 28, 2016
Find out more
Disease Analysis: Wet Age-Related Macular Degeneration
Read More
Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision. AMD is the leading cause of blindness in individuals who are over 65 years old. As the chances of experiencing any form of AMD increase with age, treatment of this disease is becoming even more important as life expectancies continue to rise in most regions.
January 27, 2022
Find out more
Evenity
Read More
Evenity (romosozumab; Amgen/UCB/Astellas) is a novel humanized monoclonal antibody therapy targeting the osteocyte-produced protein sclerostin, which inhibits bone formation in osteoblastic cells.
March 9, 2018
Find out more
Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing
May 7, 2014
Find out more
Lyxumia
Read More
Lyxumia (lixisenatide; Sanofi) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas.
November 7, 2017
Find out more
Anemia in Chronic Kidney Disease KOL Interview – US, West Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.
June 30, 2020
Find out more
U.S. Markets for Neurosurgical and Neurointerventional Products

$3,750.00

This dynamic, new report from Medtech Insight includes analyses of selected products, current/forecast markets, surgical procedure volumes, competitors, market share by supplier, and opportunities in the U.S. Neurosurgical and Neurointerventional Products Market.
September 22, 2016
Find out more
Macitenan for Pulmonary Arterial Hypertension

$89.00

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy
March 1, 2014
Find out more
Multiple Sclerosis (MS) KOL Interview – US, Midwest

$599.00

In this interview, a US-based key opinion leader (KOL) discusses typical prescribing habits for disease-modifying therapies (DMTs) in MS. This includes first-generation DMTs and the newer, more potent entrants like Ocrevus, as well as late-stage pipeline DMTs.
March 2, 2020
Find out more
ECLIPSE Psoriasis Pulse Survey

$599.00

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study
January 31, 2019
Find out more
Vigil
Read More
Vigil (Gradalis) is an autologous tumor-based vaccine incorporating a plasmid encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a novel.
October 30, 2015
Find out more
CMOs in China and India: Still the Places to be?

$5,000.00

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.
November 3, 2016
Find out more
First-In-Class Therapies’ Shrinking In-Class Monopolies

$2,995.00

Competition from drugs in the same class (with the same mechanism of action and treating the same disease) presents a clear challenge to a first-in-class market entrant. And the speed with which these competitors arrive impacts market dynamics, commercial strategies, and, increasingly, drug prices. Therapies that enjoy extended monopolies as sole entrants in a particular class have greater commercial flexibility in negotiating with payers. Multiple drugs in the same class give payers better leverage with which to negotiate rebates and discounts with drug companies.
November 15, 2018
Find out more
Spinal Fusion Implanted Instrumentation Market

$599.00

This medical market and technology report provides a comprehensive discussion of implanted instrumentation for spinal fusion.
February 28, 2018
Find out more
U.S. Markets for Interventional Cardiology Products, April 2016

$4,750.00

In the United States (U.S.), approximately 85.6 million adults have at least one type of cardiovascular disease (CVD), a broad group of disorders that affect the heart and circulatory system. Cardiovascular disease in all its forms accounts for more deaths than any other major cause in the U.S.
April 1, 2016
Find out more
Pacts in Medtech

$199.00

Pacts in Medtech – September/October 2016 – notable technology alliances, R&D partnerships and commercial collaborations disclosed in July and August 2016.
November 18, 2016
Find out more
Zontivity Approval: Views on Efficacy/Bleeding and Projected Usage Survey

$599.00

Zontivity was approved (May 8, 2014) for use with clopidogrel/aspirin, its label was relatively benign, not reporting bleeding in the overall trial, which included stroke/TIA patients who had excessive bleeding with the drug, or in ACS trial, where there was also excessive bleeding.
May 13, 2014
Find out more
Firmagon
Read More
Firmagon (degarelix; Ferring/Astellas) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly binds to GnRH receptors in the anterior pituitary gland, rapidly reducing the circulating gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and leading to the rapid suppression of testosterone in men.
January 18, 2018
Find out more
Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

$599.00

A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.
March 17, 2022
Find out more
Market Spotlight: Small-Cell Lung Cancer (SCLC)

$1,318.00

This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening

$3,750.00

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.
September 22, 2016
Find out more
Multiple Myeloma KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.
May 15, 2020
Find out more
Biosimilars Market Access in the US

$2,995.00

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.
October 23, 2015
Find out more
Disease Analysis: COVID-19 Prevention
Read More
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.
May 17, 2022
Find out more
Ganetespib
Read More
Ganetespib, under development by Synta, is a small molecule inhibitor of HSP90. HSP90 is a chaperone protein required to drive growth, proliferation, and cell survival in tumor tissue.
September 17, 2015
Find out more
Xolair
Read More
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma.
February 16, 2018
Find out more
Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *